The traditional approach of total artificial heart (TAH) and ventricul
ar assist device (VAD) development has been the mimicking of the nativ
e heart. Nonpulsatile flow using cardiopulmonary bypass has provided e
vidence of short-term physiologic tolerances. The design of nonpulsati
le TAHs and VADs has eliminated the need for valves, flexing diaphragm
s, and large ventricular volumes. However, these devices require high
efficiency power sources and reliable bearing seals or electromagnetic
bearings while simultaneously attempting to avoid thromboemboli. The
physiologic response to nonpulsatile flow is complex and variable. Whe
n compared to a pulsatile device, a nonpulsatile TAH or VAD needs to p
roduce increased flow and higher mean intravascular pressures to maint
ain normal organ function. Despite its maintaining normal organ functi
on, nonpulsatile flow does cause alterations in biochemical functions
and organ specific blood now. The combination of bioengineering superi
ority and the maintenance of physiologic homeostasis has directed futu
re TAH and VAD research towards nonpulsatile systems.